Pharmacological Characteristics of Lacobacillus gasseri OLL2809 and its Application to the Endometriosis Therapy

Masayuki Uchida
In: Journal of Women’s Health, Issues & Care · 2014 · vol. 03(04) · doi:10.4172/2325-9795.1000155 · W2313353147
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Lactobacillus gasseri OLL2809 enhanced NK cell activity, inhibited endometrial tissue growth in mice, and improved dysmenorrhea pain in patients with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

This paper describes “Pharmacological Characteristics” of the probiotic Lactobacillus gasseri OLL2809 and its application to endometriosis therapy, but the provided text contains only publisher and journal-format information rather than study design, participant/population details, experimental methods, or results. No key pharmacological findings, outcome measures, or limitations are explicitly stated in the excerpt. Because the actual scientific content is not included, it is not possible to extract the main conclusions or any explicit caveats from what is shown. This paper is centrally about endometriosis — it is presented as applying Lactobacillus gasseri OLL2809 to endometriosis therapy.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Many probiotics have been developed for the treatment of diseases. However, there is no probiotics for the treatment of endometriosis. In the pathology of endometriosis involvement of impaired peritoneal immunosurveillance systems has been well established, suggesting the impaired activity of natural killer (NK) cell in the peritoneal cavity. Therefore, Lacobacillus gasseri OLL2809 (L. gasseri OLL2809) was selected from human as a probiotic Lactobacillus to exhibit a strong stimulatory activity for IL-12 (p70) production followed by the activation of NK cell. In a mice endometriosis model, OLL2809 significantly inhibited the growth of the endometrial tissue. In a rat implanted endometriosis model, the healing of the endometriosis was significantly enhanced by the treatment with L. gasseri OLL2809. In clinical study enrolled by patients with endometriosis, L. gasseri OLL2809 showed significant efficacy on the pain intensity at the menstrual period and significant improvement on the verbal rating scale of dysmenorrhea, although serum level of CA-125 was not affected by the ingestion of L. gasseri OLL2809. No clinical adverse effect was observed by the treatment with L. gasseri OLL2809. These findings show that OLL2809 is useful and safety probiotic to improve quality of life (QOL) in the endometrial patients.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (42)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0 · commercial use OK